Judith Hey‐Hadavi

1.0k total citations
25 papers, 744 citations indexed

About

Judith Hey‐Hadavi is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Judith Hey‐Hadavi has authored 25 papers receiving a total of 744 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Endocrinology, Diabetes and Metabolism, 7 papers in Surgery and 4 papers in Molecular Biology. Recurrent topics in Judith Hey‐Hadavi's work include Growth Hormone and Insulin-like Growth Factors (10 papers), Pituitary Gland Disorders and Treatments (8 papers) and Oral microbiology and periodontitis research (4 papers). Judith Hey‐Hadavi is often cited by papers focused on Growth Hormone and Insulin-like Growth Factors (10 papers), Pituitary Gland Disorders and Treatments (8 papers) and Oral microbiology and periodontitis research (4 papers). Judith Hey‐Hadavi collaborates with scholars based in United States, Sweden and United Kingdom. Judith Hey‐Hadavi's co-authors include Steven P. Engebretson, John T. Grbic, Beverly M. K. Biller, Dan Hsu, Ira B. Lamster, Christian J. Strasburger, Roy Gomez, Thierry Brue, Natasa Rajicic and A. J. van der Lely and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Journal Of Clinical Periodontology and Journal of Periodontology.

In The Last Decade

Judith Hey‐Hadavi

25 papers receiving 715 citations

Peers

Judith Hey‐Hadavi
A. C. Thai Singapore
Arturo R. Rolla United States
D M Large United Kingdom
K M Cochran United Kingdom
Tejas P. Singh Australia
A. C. Thai Singapore
Judith Hey‐Hadavi
Citations per year, relative to Judith Hey‐Hadavi Judith Hey‐Hadavi (= 1×) peers A. C. Thai

Countries citing papers authored by Judith Hey‐Hadavi

Since Specialization
Citations

This map shows the geographic impact of Judith Hey‐Hadavi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judith Hey‐Hadavi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judith Hey‐Hadavi more than expected).

Fields of papers citing papers by Judith Hey‐Hadavi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judith Hey‐Hadavi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judith Hey‐Hadavi. The network helps show where Judith Hey‐Hadavi may publish in the future.

Co-authorship network of co-authors of Judith Hey‐Hadavi

This figure shows the co-authorship network connecting the top 25 collaborators of Judith Hey‐Hadavi. A scholar is included among the top collaborators of Judith Hey‐Hadavi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Judith Hey‐Hadavi. Judith Hey‐Hadavi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
2.
Fleseriu, Maria, Dagmar Führer‐Sakel, A. J. van der Lely, et al.. (2021). More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY. European Journal of Endocrinology. 185(4). 525–538. 42 indexed citations
3.
Vila, Greisa, Anton Luger, Aart Jan van der Lely, et al.. (2020). Hypertension in Acromegaly in Relationship to Biochemical Control and Mortality: Global ACROSTUDY Outcomes. Frontiers in Endocrinology. 11. 577173–577173. 18 indexed citations
4.
Tritos, Nicholas A., Anders Mattsson, Greisa Vila, et al.. (2020). All-cause mortality in patients with acromegaly treated with pegvisomant: an ACROSTUDY analysis. European Journal of Endocrinology. 182(3). 285–292. 8 indexed citations
5.
Buttgereit, Frank, Vibeke Strand, Eun Bong Lee, et al.. (2019). Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study. RMD Open. 5(1). e000889–e000889. 32 indexed citations
6.
Wajnrajch, Michael P., Roy Gomez, Judith Hey‐Hadavi, et al.. (2019). SUN-LB080 ACROSTUDY - Safety and Efficacy of a Cohort of 110 Naïve Patients with Acromegaly Treated with Pegvisomant. Journal of the Endocrine Society. 3(Supplement_1). 3 indexed citations
7.
Brue, Thierry, Anders Lindberg, Aart Jan van der Lely, et al.. (2018). Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy. Endocrine. 63(3). 563–572. 26 indexed citations
8.
Loftus, Jane, et al.. (2018). Targeted literature review of the humanistic and economic burden of adult growth hormone deficiency. Current Medical Research and Opinion. 35(6). 963–973. 8 indexed citations
9.
Conrado, Daniela J., Sriram Krishnaswami, Satoshi Shoji, et al.. (2016). Predicting the probability of successful efficacy of a dissociated agonist of the glucocorticoid receptor from dose–response analysis. Journal of Pharmacokinetics and Pharmacodynamics. 43(3). 325–341. 17 indexed citations
11.
Lely, A. J. van der, Beverly M. K. Biller, Thierry Brue, et al.. (2012). Long-Term Safety of Pegvisomant in Patients with Acromegaly: Comprehensive Review of 1288 Subjects in ACROSTUDY. The Journal of Clinical Endocrinology & Metabolism. 97(5). 1589–1597. 168 indexed citations
12.
Pleil, Andreas M., et al.. (2012). Psychometric Assessment of the Injection Pen Assessment Questionnaire (IPAQ): measuring ease of use and preference with injection pens for human growth hormone. Health and Quality of Life Outcomes. 10(1). 126–126. 9 indexed citations
13.
Engebretson, Steven P. & Judith Hey‐Hadavi. (2011). Sub-antimicrobial doxycycline for periodontitis reduces hemoglobin A1c in subjects with type 2 diabetes: A pilot study. Pharmacological Research. 64(6). 624–629. 55 indexed citations
15.
Willavize, Susan, Miia Kivipelto, David L. Sparks, et al.. (2009). P1‐260: Disease progression of cognitive impairment in Alzheimer's disease: A model‐based approach. Alzheimer s & Dementia. 5(4S_Part_8). 1 indexed citations
16.
Jones, Roy, Miia Kivipelto, Howard Feldman, et al.. (2008). The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Design and baseline characteristics. Alzheimer s & Dementia. 4(2). 145–153. 53 indexed citations
17.
Leiter, Lawrence A., D. J. Betteridge, Antônio Roberto Chacra, et al.. (2006). AUDIT study. Evidence of global undertreatment of dyslipidaemia in patients with type 2 diabetes mellitus. The British Journal of Diabetes. 6(1). 31–40. 16 indexed citations
18.
Engebretson, Steven P., et al.. (2006). The influence of diabetes on gingival crevicular fluid β‐glucuronidase and interleukin‐8. Journal Of Clinical Periodontology. 33(11). 784–790. 51 indexed citations
19.
Hey‐Hadavi, Judith, et al.. (2006). Tolerability of atorvastatin in a population aged ≥65 years: A retrospective pooled analysis of results from fifty randomized clinical trials. ˜The œAmerican journal of geriatric pharmacotherapy. 4(2). 112–122. 18 indexed citations
20.
Engebretson, Steven P., et al.. (2004). Gingival Crevicular Fluid Levels of Interleukin‐1β and Glycemic Control in Patients With Chronic Periodontitis and Type 2 Diabetes. Journal of Periodontology. 75(9). 1203–1208. 143 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026